Log In Sign up
The largest database of trusted experimental protocols
> Devices > Medical Device > Nasal Cannula

Nasal Cannula

Nasal cannulas are medical devices used to deliver oxygen or other gases directly to the nose.
They consist of a thin, flexible tube that fits over the ears and under the nose, with two prongs that insert into the nostrils.
Nasal cannulas are commonly used to treat respiratory conditions, such as COPD, asthma, and sleep apnea, by supplying supplemental oxygen.
They are generally more comfortable and less intrusive than face masks or other oxygen delivery methods.
Researchers studying nasal cannula design, usage, and efficacy can utilize PubCompare.ai's AI-powered platform to optimize their research protocols, locate the best existing protocols, and enhance the reproducibility and accuracy of their findings.

Most cited protocols related to «Nasal Cannula»

1
Diagnostic Protocol for Novel Coronavirus

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Adenovirus Infections Adrenal Cortex Hormones Antibiotics Bacteria Biological Assay Blood Bronchi Bronchoalveolar Lavage Fluid Complete Blood Count COVID 19 Creatine Kinase Electrolytes Feces Genes, env Influenza Influenza in Birds isolation Kidney Lactate Dehydrogenase Liver Mechanical Ventilation Methylprednisolone Middle East Respiratory Syndrome Coronavirus Nasal Cannula Nose Oligonucleotide Primers Oseltamivir Oxygen Parainfluenza Pathogenicity Patients Pharynx Physical Examination Physicians Pneumonia Real-Time Polymerase Chain Reaction Respiratory Rate Respiratory Syncytial Virus Respiratory System SARS-CoV-2 Serum Severe acute respiratory syndrome-related coronavirus Sputum Tests, Blood Coagulation Tests, Diagnostic Therapeutics Treatment Protocols Virus Virus Release
2
Evaluating Bronchopulmonary Dysplasia Definitions
We evaluated 18 prespecified, severity-graded BPD definitions (Figure 1). Definition 1 was constructed to closely resemble the 2001 NIH consensus definition, with the modification that currently unclassifiable infants receiving high-flow (>2 L/min) nasal cannula at 36 weeks’ PMA were grouped with those treated with noninvasive positive airway pressure (14 (link)). The remaining 17 definitions modified these diagnostic criteria to address the following knowledge gaps: 1) how best to classify BPD severity among infants receiving low-flow (≤2 L/min) versus high-flow (>2 L/min) nasal cannula at 36 weeks’ PMA, 2) whether inclusion of a distinct severity level for infants receiving invasive mechanical ventilation at 36 weeks’ PMA improves prediction of adverse childhood outcomes, and 3) whether eliminating the current requirement that infants must receive at least 28 days of supplemental oxygen before 36 weeks’ PMA to establish a diagnosis of BPD affects prognostic accuracy. Of note, the oxygen reduction test was not used to determine oxygen dependency in this analysis, because only 57% (452 of 791) of eligible babies underwent testing (17 (link)).
Jensen E.A., Dysart K., Gantz M.G., McDonald S., Bamat N.A., Keszler M., Kirpalani H., Laughon M.M., Poindexter B.B., Duncan A.F., Yoder B.A, & Eichenwald E.C. (2019). The Diagnosis of Bronchopulmonary Dysplasia in Very Preterm Infants. An Evidence-based Approach. American Journal of Respiratory and Critical Care Medicine, 200(6), 751-759.
Publication 2019
Diagnosis Hypoxia Infant Mechanical Ventilation Nasal Cannula Oxygen Oxygen-28 Pressure Prognosis
3
Comparative Effectiveness of Surfactant Therapies

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
beractant Birth calfactant Continuous Positive Airway Pressure Diagnosis Ethics Committees, Research Gestational Age Infant Mechanical Ventilation Nasal Cannula Oxygen Pharmaceutical Preparations Pneumothorax poractant alfa Pulmonary Emphysema Respiratory Function Tests Respiratory Rate Surfactants Syndrome Transients
4
Computational Fluid Dynamics Simulations of Nasal and Oral Aerosol Deposition
The CFD simulations performed were similar to the previous nasal ECG (12 (link)) and oral EEG (18 (link)) studies and employed the Fluent 12 (ANSYS Inc.) software supplemented with user routines. In brief, a low Reynolds number (LRN) k-ω turbulence model was used to simulate the flow, which can be laminar, transitional, or turbulent at different locations in the flow field. This turbulence model has previously been used for the successful prediction of aerosol transport and deposition in upper airway models (26 (link),28 (link),29 (link)). To evaluate the variable temperature and relative humidity fields, the coupled governing equations of heat and mass transport, reported in detail by Longest and Xi (30 ) and Longest et al.(31 ), were used. Lagrangian transport equations coupled with user-defined functions were employed to estimate the particle trajectories, growth, and deposition. User-defined functions were implemented to improve estimation of near-wall conditions and to simulate the aerosol evaporation and condensation in the complex three-dimensional temperature and humidity fields (12 (link)). User-defined functions were also used to account for anisotropic near-wall turbulent dispersion, Brownian diffusion of the initially submicrometer aerosols, and near-wall interpolation of fluid velocities (12 (link)). Our previous studies have demonstrated that this combination of a commercial code with multiple user-defined functions is capable of accurately capturing particle deposition arising from inertia, sedimentation, diffusion, and turbulent dispersion (19 , 31 ). The Kelvin effect, influences of excipient and drug hygroscopicity, and the effect of droplet temperature on surface vapor pressure were considered in the droplet size change calculations based on previous studies (12 (link)). The influence of the droplet on the carrier phase was neglected and a one-way coupled approach was implemented in the model. The details of solving the above equations using realistic boundary conditions can be found in Longest et al. (12 (link)) and Tian et al. (18 (link)).
For simulating droplet trajectories and aerosol size increase, initially monodisperse size distributions were implemented. Condensational growth of the aerosols then led to a polydisperse aerosol size distribution within the airway models. With the control experiments, an initial droplet size of 3.6 μm was found to match the experimentally measured aerosol size exiting the nasal cannula and entering the NMT model. The aerosol size exiting the Aeroneb Lab nebulizer could not be implemented directly due to high depositional losses in the neonatal T-connector, which reduced the MMAD of the aerosol and was not included in the CFD model. For the EEG and ECG simulations, the experimentally measured size exiting the mixer tubing (900 nm) was implemented at the model inlet. In all droplet simulations, 9000 initial particles were injected into the steady state flow stream and increasing this number had a negligible effect on deposition fractions.
The computational mesh was constructed using the ANSYS ICEM 10 package (Ansys Inc., Canonsburg, PA) and consisted of tetrahedral and hexahedral elements. Hexahedral control volumes were used primarily in the connective tubing, cannula geometry, and tracheal region, whereas tetrahedral elements with a thin layer of near-wall wedge control volumes were used to resolve the nasal passages through the pharynx. Grid density testing produced convergent results in terms of regional deposition for a control volume cell count of approximately 1.3 million for the EEG NMT geometry and 1.5 million for the ECG NMT model.
Golshahi L., Tian G., Azimi M., Son Y.J., Walenga R., Longest P.W, & Hindle M. (2013). The Use of Condensational Growth Methods for Efficient Drug Delivery to the Lungs during Noninvasive Ventilation High Flow Therapy. Pharmaceutical research, 30(11), 2917-2930.
Publication 2013
Anisotropy Cannula Diffusion Excipients Humidity Infant, Newborn Nasal Cannula Nasal Cavity Nebulizers Nose Pharmaceutical Preparations Pharynx Trachea Training Programs Vapor Pressure
5
Clinical Progression and Recovery Measurement for COVID-19
According to the definition of the KCDC,8 a confirmed case was defined as a patient with a positive result in the real-time reverse transcription polymerase chain reaction (rRT-PCR) assay based test for SARS-CoV-2 in upper respiratory specimens (nasopharyngeal and oropharyngeal swabs), with or without a lower respiratory specimen (sputum), regardless of symptoms. The criteria for discharge from hospital and ending isolation were: 1) symptomatic improvement and afebrile; and 2) rRT-PCR negative tests at 24 hours intervals.
To measure the clinical progression and recovery of a patient with COVID-19, we modified an ordinal scale and defined the severity scores as follows9 (link): 1) no limitation of daily activities; 2) limitation of daily activities but no need for supplemental oxygen therapy; 3) need for supplemental oxygen therapy via nasal cannula; 4) need for supplemental oxygen therapy via facial mask; 5) need for high-flow supplemental oxygen therapy or noninvasive mechanical ventilation; 6) need for invasive mechanical ventilation; 7) multi-organ failure or the need for extracorporeal membrane oxygenation (ECMO) therapy; 8) death. Recovery was defined as a score of 1 or 2, or discharge to home and release from isolation.
Sung H.K., Kim J.Y., Heo J., Seo H., Jang Y.S., Kim H., Koh B.R., Jo N., Oh H.S., Baek Y.M., Park K.H., Shon J.A., Kim M.C., Kim J.H., Chang H.H., Park Y., Kang Y.M., Lee D.H., Oh D.H., Park H.J., Song K.H., Lee E.K., Jeong H., Lee J.Y., Ko J.Y., Choi J., Ryu E.H., Chung K.H, & Oh M.D. (2020). Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea, January–May 2020. Journal of Korean Medical Science, 35(30), e280.
Publication 2020
Biological Assay COVID 19 Extracorporeal Membrane Oxygenation Face isolation Mechanical Ventilation Multiple Organ Failure Nasal Cannula Nasopharynx Noninvasive Ventilation Oropharynxs Patients Respiratory Rate Reverse Transcriptase Polymerase Chain Reaction SARS-CoV-2 Sputum Therapeutics Therapies, Oxygen Inhalation

Most recents protocols related to «Nasal Cannula»

1
Mechanical Ventilation Strategies for Severe Hypoxemia
Among mechanically ventilated patients, TTE was performed in volume-assist control mode, with a target tidal volume (VT) of 6 mL/kg of predicted body weight. In patients with severe hypoxemia (PaO2/FiO2 ratio < 100), PEEP was titrated to avoid exceeding plateau pressure values (Pplat) greater than 30 cm H2O and obtaining a driving pressure less than 15 cm H2O. If Pplat exceeded this maximum threshold, VT was lowered until Pplat was less than 30 cm H2O. On the other hand, to counteract the effect of the reduction in VT on alveolar ventilation, the respiratory rate was increased. Fraction of inspired oxygen (FiO2) was adjusted to obtain a minimum saturation of 92%.
Spontaneously breathing patients who required oxygen were supported with nasal cannula or non-rebreathing mask oxygenator delivering a minimum oxygen flow to achieve SpO2 greater than 92%. Setting primary focus on health-care personnel security, no patient in our ICU received non-invasive mechanical ventilation (e.g. continuous positive airway pressure, non-invasive positive pressure ventilation, or high-flow nasal cannula) due to the risk of aerosol dispersion.11 (link)
Carboni Bisso I., Ruiz V., Falconi M., Baglioni M., Villanueva E., Huespe I., Di Stefano S., Las Heras M, & Sinner J. (2023). Echocardiographic detection of transpulmonary bubble transit during coronavirus-2019 disease (COVID-19). Acta Colombiana de Cuidado Intensivo.
Publication 2023
Body Weight Continuous Positive Airway Pressure Intermittent Positive-Pressure Ventilation Nasal Cannula Noninvasive Ventilation Oxygen Oxygenators Patients Positive End-Expiratory Pressure Pressure Primary Health Care Respiratory Rate Saturation of Peripheral Oxygen Secure resin cement Tidal Volume
2
Barotrauma Incidence in COVID-19 ARDS Patients
Inclusion criteria were all adult (≥ 18 years old) patients with acute hypoxic respiratory failure admitted to the MICU. Exclusion criteria were defined as age <18 years, active pregnancy, incarceration, and incidental PCR positivity without hypoxia. Barotrauma was identified by chart review and confirmed by imaging (CXR or CT scan of the chest). Barotrauma detected post-procedure was excluded from the study.
We defined historical controls as adult patients hospitalized with a primary diagnosis of ARDS (as defined by Berlin criteria) in 2018 and 2019 prior to the onset of the COVID-19 pandemic, admitted to the MICU.
We collected baseline demographic data, comorbid conditions, measures of illness including Sequential Organ Failure Assessment (SOFA) score, and measures of oxygenation and hypoxia including PaO2/FiO2 (P/F) ratio. Support requirements for all patients including use of non-invasive positive pressure ventilation (NIPPV), high flow nasal cannula (HFNC), invasive mechanical ventilation (IMV) and extracorporeal membranous oxygenation (ECMO) were also collected.
Sharma S., Badami V., Rojas E., Sangani R., Chapman K., Avalon C., King A, & Wen S. (2023). High incidence of barotrauma in patients admitted with COVID-19 to ICU and associated mortality in rural Appalachia: An observational study. PLOS ONE, 18(3), e0282735.
Full text: Click here
Publication 2023
Adult Barotrauma Cell Respiration Chest COVID 19 Diagnosis Extracorporeal Membrane Oxygenation Hypoxia Intermittent Positive-Pressure Ventilation Mechanical Ventilation Nasal Cannula Patients Pregnancy Respiratory Distress Syndrome, Acute Respiratory Failure X-Ray Computed Tomography
3
COVID-19 Outcomes in Rheumatic Diseases
Demographic, clinical and laboratory data pertaining to both COVID-19 and RMD were recorded for all included patients according to a predesigned proforma. Clinical symptoms attributable to COVID-19, vital signs, treatment(s) administered for COVID-19 (antivirals and/or immunomodulatory therapies) and the final outcome (death or recovery) were noted. Severe and critical disease as defined by the World Health Organization (WHO) were grouped together as severe disease for the purpose of the present study and defined as the presence of oxygen saturation <90% on room air or signs of severe respiratory distress in addition to signs of pneumonia or presence of ARDS, sepsis, septic shock or other conditions that would normally require the provision of life-sustaining therapies, such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy [18 ]. In addition, based on national guidelines [19 ], non-severe disease was categorized further as moderate disease (defined by a respiratory rate >24/min or a peripheral oxygen saturation between 90 and 94%) and as mild disease when patients with RT-PCR-confirmed SARS-CoV-2 had only upper respiratory tract symptoms without any hypoxaemia or tachypnoea. Laboratory parameters recorded included haemogram, liver function tests (total and direct bilirubin, aspartate transaminase, alanine transaminase, γ-glutamyl transferase, alkaline phosphatase and serum albumin), renal function tests, CRP, ferritin, D-dimer, fibrinogen, international normalized ratio and procalcitonin (hospitalized patients only). The neutrophil-to-lymphocyte ratio was also calculated from the differential leucocyte count. Data pertaining to the type of underlying RMD, disease activity status (active vs remission) at the time of acquisition of SARS-CoV-2, and ongoing treatment [supportive, NSAIDs, glucocorticoids (GCs), conventional synthetic DMARDs (including HCQ, MTX, LEF, SSZ, AZA, MMF and CYC), biologic DMARDs (rituximab or anti TNF), antifibrotics (nintedanib or pirfenidone) or IVIG] were also noted, along with details of underlying medical co-morbidities. DMARDs were also categorized into immunomodulators (MTX, LEF and SSZ) and immunosuppressants (CYC, AZA, MMF and biologic DMARDs) for the purpose of predictor analysis.
Outcomes of interest included the proportion of patients with severe COVID-19, mortality (as a percentage), hospitalization (as a percentage), intensive care unit (ICU) stay (as a percentage), the requirement for respiratory support (as a percentage) and its level (oxygen delivered by face mask or nasal prongs, non-rebreathing mask, high-flow nasal cannula, non-invasive ventilation or invasive mechanical ventilation). Predictors of COVID-19 severity, mortality and hospitalization were determined.
Mathew J., Jain S., Susngi T., Naidu S., Dhir V., Sharma A., Jain S, & Sharma S.K. (2023). Predictors of COVID-19 severity and outcomes in Indian patients with rheumatic diseases: a prospective cohort study. Rheumatology Advances in Practice, 7(1), rkad025.
Full text: Click here
Publication 2023
Alanine Transaminase Alkaline Phosphatase Anti-Inflammatory Agents, Non-Steroidal Antirheumatic Drugs, Disease-Modifying Antiviral Agents Bilirubin Biological Response Modifiers Biopharmaceuticals COVID 19 Face Ferritin fibrin fragment D Fibrinogen gamma-Glutamyl Transpeptidase Glucocorticoids Hospitalization Immunomodulation Immunosuppressive Agents International Normalized Ratio Intravenous Immunoglobulins Kidney Function Tests Leukocyte Counts, Differential Liver Function Tests Lymphocyte Mechanical Ventilation Nasal Cannula Neutrophil nintedanib Noninvasive Ventilation Nose Oxygen Oxygen Saturation Patients pirfenidone Pneumonia Procalcitonin Respiratory Distress Syndrome, Adult Respiratory Rate Reverse Transcriptase Polymerase Chain Reaction Rituximab SARS-CoV-2 Saturation of Peripheral Oxygen Septicemia Septic Shock Serum Albumin Signs, Vital Signs and Symptoms, Respiratory Transaminase, Serum Glutamic-Oxaloacetic Vasoconstrictor Agents
4
Polysomnography for Obstructive Sleep Apnea
In-laboratory PSG was performed utilizing ResMed Embla N7000 (ResMed, San Diego, CA, USA) and Embla MPR (Natus Medical, Pleasanton, CA, USA). PSG includes various sensors (i.e. electroencephalogram, electrooculogram, electromyogram of the chin and leg, a nasal cannula, oral–nasal thermistor, bands for the chest and abdomen, pulse oximetry, and a piezoelectric vibration sensor). All of the signals were recorded using RemLogic software (version 3.41, Embla, Thornton, CO, USA) and scored by certified PSG technologists per the Americana Academy of Sleep Medicine (AASM) Scoring Manual.25 For snoring which serves as an indicator of upper airway obstruction, these events were assessed by a piezoelectric vibration sensor placed on the triangle of the neck. Technically, this sensor measures frequencies of oscillations at the skin surface, thereby generating a piezoelectric signal to represent the snoring waveform. Snoring events were defined as protruding from the background and being synchronized with breathing, except for the body movement time. Piezoelectric signals were recorded at a sampling rate of 200 Hz and with AASM-recommended filter settings (low frequency of 10 Hz and high frequency of 100 Hz). Regarding OSA severity, the AHI, defined as the number of apneic and hypopneic events of the total sleep time, was obtained, and this index was further divided into four OSA levels, namely normal (AHI: <5 times/h), mild (5 ≤ AHI <15 times/h), moderate (15≤ AHI <30 times/h), and severe (AHI ≥30 times/h).26 (link)
Tsai C.Y., Liu W.T., Hsu W.H., Majumdar A., Stettler M., Lee K.Y., Cheng W.H., Wu D., Lee H.C., Kuan Y.C., Wu C.J., Lin Y.C, & Ho S.C. (2023). Screening the risk of obstructive sleep apnea by utilizing supervised learning techniques based on anthropometric features and snoring events. Digital Health, 9, 20552076231152751.
Publication 2023
Abdomen Airway Obstruction Apnea Chest Chin Electroencephalography Electromyography Electrooculograms Movement Nasal Cannula Neck Nose Oximetry, Pulse Pharmaceutical Preparations Skin Sleep Vibration
5
Clinical Characteristics and Outcomes of Pediatric COVID-19
We reviewed the medical charts of the study patients using standardized case report forms. Data regarding the primary reason for hospital admission, symptoms at admission, underlying medical conditions, clinical diagnosis of SARS-CoV-2 infection, the need for respiratory support, and specific therapy for COVID-19 were collected.
In Korea, mandatory facility quarantine and hospitalization regulations were completely lifted in late November 2021. Since the decision for hospitalization and allocation of hospitalization resources to COVID-19 patients were primarily under the management of the KCDA and guided by the national COVID-19 response system, there were discrepancies with clinicians’ judgment on the need for hospitalization. Therefore, we reclassified ‘necessary admission’ based on the severity of COVID-19-related symptoms and signs and the risk for progression to severe illness in the adjusted comparisons of clinical severity and outcomes during the two periods. Reasons for admission that were likely not COVID-19 related included categories such as simple isolation, inpatient surgery, or asymptomatic nosocomial infection (positive for SARS-CoV-2 in universal inpatient screening). Primary classification of necessary admission was performed on the basis of the researchers’ judgment at each study site. Subsequently, two researchers (SHC and KWY) conducted a secondary review based on the collected case report form data. The Pediatric Medical Complexity Algorithm was used to categorize patients with no chronic disease, noncomplex chronic disease, and complex chronic disease.12 (link)13 (link) The presence of complex chronic disease was defined as having chronic conditions in ≥ 2 body systems, a progressive chronic disease, malignancy, or continuous dependence on technology for at least 6 months.13 (link) Obesity was defined as the presence of an age-sex-standardized weight-for-height (aged 0–23 months) or body mass index (aged ≥ 2 years) ≥ 95th percentile based on the 2017 Korean National Growth Chart.14 (link) Obesity was not included in the category of chronic diseases.
The severity of COVID-19 was defined as follows: mild, upper respiratory infection not requiring oxygen or a simple febrile seizure; moderate, lower respiratory tract infection not requiring oxygen, croup/a febrile seizure requiring oxygen or a change in mental status without seizure; severe, lower respiratory tract infection requiring oxygen via nasal prongs or a mask, COVID-19-related conditions requiring a high-flow nasal cannula at ≤ 2 L/kg/min, or COVID-19-related end-organ (such as brain, kidney, or heart) damage; critical, unstable COVID-19-related conditions requiring ICU admission, mechanical ventilation, or extracorporeal membrane oxygenation, sepsis/septic shock, multiple organ failure, or death. To compare the characteristics according to severity, moderate, severe, and critical conditions were classified as serious illness.
Choi S.H., Choi J.H., Lee J.K., Eun B.W., Song S.H., Ahn B., Kim Y.K, & Yun K.W. (2023). Clinical Characteristics and Outcomes of Children With SARS-CoV-2 Infection During the Delta and Omicron Variant-Dominant Periods in Korea. Journal of Korean Medical Science, 38(9), e65.
Publication 2023
Brain Chronic Condition COVID 19 Croup Diagnosis Disease, Chronic Disease Progression Extracorporeal Membrane Oxygenation Febrile Convulsions Heart Hospitalization Human Body Index, Body Mass Infections, Hospital Inpatient isolation Kidney Koreans Malignant Neoplasms Mechanical Ventilation Multiple Organ Failure Nasal Cannula Nose Obesity Operative Surgical Procedures Oxygen Patients Quarantine Respiratory Rate Respiratory Tract Infections SARS-CoV-2 Seizure, Febrile, Simple Seizures Septic Shock Therapeutics Upper Respiratory Infections

Top products related to «Nasal Cannula»

1
Airvo 2 by Fisher & Paykel Healthcare
Sourced in New Zealand
The Airvo 2 is a heated humidifier that delivers warm, humidified respiratory gases to patients who require respiratory support. It is designed to provide high-flow nasal therapy, which helps to improve patient comfort and respiratory function.
2
Optiflow by Fisher & Paykel Healthcare
Sourced in New Zealand
Optiflow is a high-flow nasal cannula system designed to provide respiratory support. It delivers heated and humidified air to the patient's nasal airway, facilitating oxygen delivery and improving breathing comfort.
3
Mp150 by Biopac
Sourced in United States, Canada, United Kingdom, Germany
The MP150 is a data acquisition system designed for recording physiological signals. It offers high-resolution data capture and features multiple input channels to accommodate a variety of sensor types. The MP150 is capable of acquiring and analyzing data from various biological and physical measurements.
4
Apnealink plus by Resmed
Sourced in Australia, United States
The ApneaLink Plus is a portable sleep apnea screening device. It measures airflow, respiratory effort, and blood oxygen levels to detect the presence of sleep-disordered breathing.
5
Powerlab by ADInstruments
Sourced in Australia, United States, United Kingdom, New Zealand, Germany, Japan, Spain, Italy, China
PowerLab is a data acquisition system designed for recording and analyzing physiological signals. It provides a platform for connecting various sensors and transducers to a computer, allowing researchers and clinicians to capture and analyze biological data.
6
Ml141 by ADInstruments
Sourced in United States
The ML141 is a versatile four-channel bioamplifier designed for recording and analyzing biological signals. It provides high-quality amplification and conditioning of electrophysiological signals from various transducers and electrodes.
7
Opt944 by Fisher & Paykel Healthcare
Sourced in New Zealand
The OPT944+ is a lab equipment product from Fisher & Paykel Healthcare. It is designed for medical and laboratory use.
8
Mr850 by Fisher & Paykel Healthcare
Sourced in New Zealand
The MR850 is a respiratory humidifier designed for use in medical environments. It is intended to provide humidification for respiratory gases delivered to patients.
9
Apnealink air by Resmed
Sourced in Australia, United States
The ApneaLink Air is a compact, portable sleep apnea screening device. It is designed to monitor and record respiratory parameters during sleep. The device is intended to assist healthcare professionals in the diagnosis and management of sleep-related breathing disorders.
10
Nexfin by Edwards Lifesciences
Sourced in Canada, United States
The Nexfin is a non-invasive medical device that continuously measures arterial blood pressure. It uses a finger cuff to detect changes in the volume of blood vessels and provides real-time monitoring of blood pressure.

More about "Nasal Cannula"

Nasal Cannulas: Delivering Oxygen with Comfort and Precision Nasal cannulas are versatile medical devices used to administer oxygen or other gases directly to the nose.
These thin, flexible tubes fit comfortably over the ears and under the nose, with two prongs that insert into the nostrils.
Nasal cannulas are a popular choice for treating respiratory conditions like COPD (Chronic Obstructive Pulmonary Disease), asthma, and sleep apnea, as they provide supplemental oxygen in a less intrusive way compared to face masks or other oxygen delivery methods.
Researchers studying nasal cannula design, usage, and efficacy can leverage advanced tools like PubCompare.ai's AI-powered platform to optimize their research protocols, locate the best existing protocols, and enhance the reproducibility and accuracy of their findings.
This can be particularly useful when exploring related devices and technologies, such as the Airvo 2 high-flow nasal cannula system, Optiflow nasal cannula, MP150 research system, ApneaLink Plus home sleep apnea test, PowerLab data acquisition systems, ML141 flow sensors, OPT944+ nasal cannulas, MR850 heated humidifier, and the ApneaLink Air home sleep apnea test device.
By tapping into the wealth of information available on these products and their applications, researchers can gain valuable insights to improve their nasal cannula research and push the boundaries of what's possible in respiratory care.
With the right tools and resources at their fingertips, they can enhance the quality, efficiency, and impact of their work, ultimately leading to better patient outcomes.